8-K filing — EyePoint, Inc. (EYPT)
Filed: 2026-09-10 AccNo: 0001193125-26-387197 Size: 24 MB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
US stocks mixed, Dow falls 150 points. Dow down 0.31%, NASDAQ up 0.03%, S&P 500 down 0.12%. Tech shares up 0.4%, consumer staples down 0.8%.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-09-10 AccNo: 0001193125-26-387197 Size: 24 MB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
EyePoint Inc. (NASDAQ: EYPT) announced disappointing Phase 3 clinical trial results for DURAVYU on August 17, 2026, failing to meet its primary endpoint in the LUGANO trial for wet age-related macular degeneration treatment. The stock subsequently dropped over 66%, prompting a securities litigation investigation by KTMC on behalf of affected investors.
Wall Street analysts changed outlook on top companies. Check out complete rating changes, including upgrades/downgrades, on our page.
FAST TRACK GROUP (NASDAQ:FTRK) ("Fast Track" or the "Company"), a leading entertainment-focused event management and celebrity agency company, announced that its subsidiary Fast Track Entertainment
Strategic collaboration brings together artist expertise, digital content, and brand partnerships to help artists expand their reach, grow their audiences, and unlock new commercial opportunities across Southeast